Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Grul, P."'
Autor:
Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100624- (2024)
Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients wit
Externí odkaz:
https://doaj.org/article/5159d19b07b0438c8a46366db7862e0c
Large amplitude whistler waves at frequencies of 0.2 to 0.4 times electron cyclotron frequency are frequently observed in the solar wind. The waves are obliquely propagating close to the resonance cone, with significant electric fields parallel to th
Externí odkaz:
http://arxiv.org/abs/2003.09659
Autor:
Edward B. Garon, Carla Visseren-Grul, Maria Teresa Rizzo, Tarun Puri, Suresh Chenji, Martin Reck
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionIn the REVEL trial, ramucirumab plus docetaxel demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared with placebo plus docetaxel for treatment of metastat
Externí odkaz:
https://doaj.org/article/b54245a672d24f66a33952de0821e809
Autor:
Cohen, Z. A., Cattell, C. A., Breneman, A. W., Davis, L., Grul, P., Kersten, K., Wilson III, L. B., Wygant, J. R.
We present STEREO observations within 1500 proton gyroradii of 12 interplanetary shocks, with long-duration burst mode electric field acquisition by S/WAVES enabling observation of the evolution of waves throughout the entire ramp of interplanetary s
Externí odkaz:
http://arxiv.org/abs/1909.08176
Autor:
Nishio, Makoto, Negrao, Marcelo Vailati, Arbour, Kathryn C., Burns, Timothy F., Cappuzzo, Federico, Dingemans, Anne-Marie C., Girard, Nicolas, Gronberg, Bjorn Henning, Hochmair, Maximilian, Leal, Ticiana, Lindsay, Colin R., Lu, Shun, Paz-Ares, Luis G., Reck, Martin, Sabari, Joshua K., Spira, Alexander I., William Jr., William Nassib, Chen, Aaron, Visseren Grul, Carla M., Peters, Solange
Publikováno v:
Journal of Clinical Oncology; 2024 Supplement, Vol. 42, pTPS218-TPS218, 24p
Autor:
Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 4, Pp 100303- (2022)
Introduction: Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period
Externí odkaz:
https://doaj.org/article/2c15ffbd66fc4dc2bedf92f859b0dd3f
Autor:
Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100171- (2021)
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic
Externí odkaz:
https://doaj.org/article/3e75f1f8e2034c7bb7923044f4c4d8a7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S Ponce Aix, S Novello, EB Garon, K Nakagawa, E Nadal, D Moro-Sibilot, M Alonso Garcia, E Fabre, B Frimodt-Moller, AH Zimmermann, CM Visseren-Grul, M Reck
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100378- (2021)
Background: In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior PFS for ramucirumab plus erlotinib (RAM + ERL) over placebo plus erlotinib (
Externí odkaz:
https://doaj.org/article/311be659bf0b4a30a008b49186ae088d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.